DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Phase 3

Completed

Conditions: Streptococcus Pneumoniae

Interventions: Biological: Prevnar
Biological: Pneumo 23

First Posted Date: 2008-01-15

Last Posted Date: 2015-06-18

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 339

Registration Number: NCT00594347

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: 2007-2008 Influenza Virus Vaccine

First Posted Date: 2007-11-20

Last Posted Date: 2016-04-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 34

Registration Number: NCT00561002

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Flu-ID 15μg
Biological: Inactivated adjuvanted Influenza Vaccine

First Posted Date: 2007-11-06

Last Posted Date: 2018-03-16

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 795

Registration Number: NCT00554333

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

Phase 2

Completed

Conditions: Influenza
Orthomyxoviridae Infections

Interventions: Biological: A/H5N1 inactivated, split-virion influenza virus

First Posted Date: 2007-10-17

Last Posted Date: 2014-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 100

Registration Number: NCT00545701

Immunology and Safety of Menactra® in Children in Saudi Arabia

Phase 3

Completed

Conditions: Meningitis
Meningococcemia

First Posted Date: 2007-10-03

Last Posted Date: 2016-04-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 238

Registration Number: NCT00539032

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™

Phase 3

Completed

Conditions: Tetanus
Pertussis
Hepatitis B
Diphtheria
Haemophilus Influenzae Type b

Interventions: Biological: DTaP-HB-PRP~T vaccine
Biological: Tritanrix-HepB/Hib™
Biological: Oral Polio Vaccine

First Posted Date: 2007-09-26

Last Posted Date: 2013-11-21

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 362

Registration Number: NCT00534833

Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

Completed

Conditions: Diphtheria
Pertussis

Interventions: Biological: Tetanus and diphtheria toxoids and acellular pertussis

First Posted Date: 2007-09-05

Last Posted Date: 2014-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 7156

Registration Number: NCT00524732

Trial to Describe the Safety and Immunogenicity of Fluzone®

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Inactivated, Split-Virion Influenza Virus

First Posted Date: 2007-09-05

Last Posted Date: 2016-04-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 124

Registration Number: NCT00524940

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants

Phase 3

Completed

Conditions: Pertussis
Tetanus
Hepatitis B
Influenza
Diphtheria

Interventions: Biological: DTaP-HB PRP~T Combined Vaccine
Biological: DTaP-HB-PRP~T vaccine
Biological: Oral Polio Vaccine

First Posted Date: 2007-08-10

Last Posted Date: 2016-08-02

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1843

Registration Number: NCT00514709

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Phase 2

Completed

Conditions: Influenza
Orthomyxoviridae Infections
Influenza A Virus Infection

Interventions: Biological: A/H5N1 Inactivated, split-virion pandemic influenza vaccine
Biological: A/H5N1 Inactivated, split virion pandemic influenza vaccine

First Posted Date: 2007-06-27

Last Posted Date: 2014-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 240

Registration Number: NCT00491985

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy